Home » Posts tagged with » AstraZeneca
AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter’s DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), which is being developed for the treatment of multiple tumor types. Daiichi Sankyo is developing the antibody drug conjugate for multiple tumors […]

COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response

COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine (AZD1222) to be well tolerated besides generating strong responses in all evaluated participants against the COVID-19 causing SARS-CoV-2 virus. The early-stage COVID-19 vaccine trial is being led by Oxford University, […]

Continue reading …
Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI

AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults after an acute myocardial infarction (MI) or heart attack. The fast track designation for the oral once-daily sodium-glucose co-transporter-2 (SGLT2) inhibitor is based on […]

Continue reading …
ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca

Russian pharma company R-Pharm has reportedly signed an agreement with AstraZeneca for manufacturing the ChAdOx1 nCoV-19 vaccine being developed by the latter in collaboration with UK-based Oxford University. The entire world is pinning hopes on the ChAdOx1 nCoV-19 vaccine candidate, which reportedly seems to be the most probable to become the first vaccine against the […]

Continue reading …
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL

Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination of Bcl-2 and Bruton’s Tyrosine Kinase (BTK) inhibitors in a type of lymphoma. As per the collaboration terms, Ascentage Pharma will sponsor a clinical trial to evaluate the efficacy and […]

Continue reading …
Catalent wins contract to manufacture AZD1222 COVID-19 vaccine candidate

US-based Catalent said that its subsidiary Catalent Biologics has bagged a contract to provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Anagni, Italy, and prepare for large-scale commercial supply of AZD1222, the adenovirus vector based COVID-19 vaccine candidate of the University of Oxford. Catalent said that the agreement fast tracks […]

Continue reading …
Novo Nordisk to acquire cardio-renal disease company Corvidia Therapeutics

Novo Nordisk acquisition of Corvidia : Danish pharma company Novo Nordisk has agreed to acquire Corvidia Therapeutics from life sciences venture capital firm Sofinnova Partners in a deal worth up to $2.1 billion, in a move to expand its presence in cardiovascular disease. Corvidia Therapeutics, which is based in Boston, Massachusetts, was spun out from […]

Continue reading …
CytoSorbents gets CytoSorb EU approval for removal of ticagrelor during CPB

CytoSorbents has secured approval from the European Union (EU) for its CytoSorb extracorporeal blood purification therapy for the removal of anti-platelet agent ticagrelor during surgery requiring cardiopulmonary bypass (CPB). The CytoSorb whole blood adsorber has also been given CE Mark label expansion for the indication.  It was earlier approved in the European Union for the […]

Continue reading …
AstraZeneca to sell five hypertension drugs to Atnahs Pharma

AstraZeneca has signed a deal valued at about $390 million with Atnahs Pharma, a portfolio company of Triton Fund V, to sell five of its hypertension drugs to the latter as they have lost patent protection across the world. The deal will give Atnahs Pharma the global commercial rights to the hypertension medicines – Inderal (propranolol), […]

Continue reading …
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle

Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma acquisition news. Financial details of the two deals have not been disclosed. The divestments are being taken up in an effort to wrap up the $63 billion AbbVie acquisition of […]

Continue reading …
Page 1 of 3123